Company: CERO
Filing Date: 2025-08-22
Form Type: 424B3
Source: 0001213900-25-080017
Chunk: 69

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-08-22
Form: 424B3
Chunk 69
---
continuation of the equity line program commenced under the February 2024 Purchase Agreement, the Commitment Shares issued to the Investor
pursuant to the February 2024 Purchase Agreement shall satisfy in full the Company’s obligation to deliver any additional shares
of Common Stock to the Investor as consideration for entering into the New Keystone Purchase Agreement.

On July 18, 2025, the Company sold an additional 497 shares of Series D Preferred Stock for gross cash proceeds of $432,600 in an additional closing.

On July 18, 2025, 53 shares of Series C Preferred Stock were converted into 10,600 shares of Common Stock. The conversion ratio was agreed upon by the Company and investor at a conversion price of $5.00 per share, which was lower than the conversion price based on the Series C Certificate of Designations Alternate Conversion price.

On August 20, 2025, the Company
and certain investors entered into a Stock Purchase Agreement, pursuant to which the Company sold 1,000,279 Stella D Preferred Stock for
cash proceeds of $500,000. In accordance with ASC 855-10, Subsequent Events, the Company evaluated this event under ASC 855-10-25-1
and determined that it represents a Type I subsequent event (recognized subsequent event) because the sale provided additional evidence
about conditions that existed at the balance sheet date. Accordingly, the Company determined that the fair value of the equity securities
on the date of the Fourth Securities Purchase Agreement of April 21, 2025 and June 30, 2025 was equal to $500,000.

<div align='center'>30</div>

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations provides information that CERo Therapeutics Holdings, Inc. (“the Company”) management believes is relevant to an assessment and understanding of its results of operations and financial condition. The discussion should be read together with (i) the Company’s unaudited condensed consolidated financial statements and related notes that are presented above and (ii) the Company’s audited consolidated financial statements and related notes and management’s discussion and analysis of financial condition and results of operations included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (the “SEC”) on April 15, 2025. This